OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press54210.17650/1818-8346-2022-17-2-95-106TREATMENT OF HEMATOLOGICAL MALIGNANCIES IN PATIENTS WITH COVID-19: PRO AND CONTRAЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ЗАБОЛЕВАНИЙ СИСТЕМЫ КРОВИ У ПАЦИЕНТОВ С COVID-19: ЗА И ПРОТИВMonoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contraПрименение моноклональных анти-CD20-антител в терапии лимфом в условиях пандемии COVID-19: за и противhttps://orcid.org/0000-0001-8053-9724SychevskayaK. A.СычевскаяК. А.
Russian Federation

125167, Moscow, Novyy Zykovskiy Proezd, 4

125167 Москва, Новый Зыковский проезд, 4

sychevskaya-ka@yandex.ruhttps://orcid.org/0000-0001-9086-8521KravchenkoS. K.КравченкоС. К.
Russian Federation

125167, Moscow, Novyy Zykovskiy Proezd, 4

125167 Москва, Новый Зыковский проезд, 4

National Research Center for Hematology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России14042022172951061304202213042022https://oncohematology.abvpress.ru/ongm/article/view/542

Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contraThe review presents the results of a combined analysis of literature data and own clinical observations regarding the safety and feasibility of using monoclonal anti-CD20 antibodies in the treatment of B-cell lymphoproliferative diseases during the COVID-19 pandemic. The main points of the pathogenesis of the influence of monoclonal anti-CD20 antibodies on the course of COVID-19 are described. The current trends in the modification of the accepted algorithms of lymphoproliferative diseases therapy with the inclusion of monoclonal anti-CD20 antibodies are summarized, and the possibilities of specific prevention by vaccination against COVID-19 are also considered.

В настоящем обзоре представлены результаты сочетанного анализа данных литературы и собственных клинических наблюдений относительно безопасности и целесообразности применения моноклональных анти-CD20-антител в терапии B-клеточных лимфопролиферативных заболеваний в условиях пандемии новой коронавирусной инфекции COVID-19. Изложены основные моменты патогенеза влияния моноклональных анти-CD20-антител на течение COVID-19. Обобщены современные тенденции в модификации принятых алгоритмов терапии лимфопролиферативных заболеваний с включением моноклональных анти-CD20-антител, а также рассмотрены возможности специфической профилактики путем вакцинации против COVID-19.

monoclonal anti-CD20 antibodyrituximabobinutuzumabnew coronavirus infection COVID-19lymphoproliferative diseaseB-cell non-Hodgkin lymphomavaccinationмоноклональное анти-CD20-антителоритуксимабобинутузумабновая коронавирусная инфекция COVID-19лимфопролиферативное заболеваниеB-клеточная неходжкинская лимфомавакцинопрофилактикаWang Q., Berger N.A., Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol 2021;7(2):220–7. DOI:10.1001/jamaoncol.2020.6178.Grivas P., Khaki A.R., Wise-Draper T.M. et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol 2021;32(6):787–800. DOI:10.1016/j.annonc.2021.02.024.Yang K., Sheng Y., Huang C. et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21(7):904–13. DOI:10.1016/S1470-2045(20)30310-7.Mehta V., Goel S., Kabarriti R. et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 2020;10(7):935–41. DOI:10.1158/2159-8290.CD-20-0516.Kuderer N.M., Choueiri T.K., Shah D.P. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395(10241):1907–18. DOI:10.1016/S0140-6736(20)31187-9.Lee L.Y.W., Cazier J.B., Starkey T. et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020;21(10):1309–16. DOI:10.1016/S1470-2045(20)30442-3.Dai M., Liu D., Liu M. et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 2020;10(6):783–91. DOI:10.1158/2159-8290.CD-20-0422.Martín-Moro F., Marquet J., Piris M. et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol 2020;190(1):e16–20. DOI:10.1111/bjh.16801.Malard F., Genthon A., Brissot E. et al. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant 2020;55(11):2180–4. DOI:10.1038/s41409-020-0931-4.He W., Chen L., Chen L. et al. COVID-19 in persons with haematological cancers. Leukemia 2020;34(6):1637–45. DOI:10.1038/s41375-020-0836-7.Hatzl S., Eisner F., Schilcher G. et al. Response to “COVID-19 in persons with haematological cancers”. Leukemia 2020;34(8):2265–70. DOI:10.1038/s41375-020-0914-x.Aries J.A., Davies J.K., Auer R.L. et al. Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. Br J Haematol 2020;190(2):e64–7. DOI:10.1111/bjh.16852.Wu Y., Chen W., Li W. et al. Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 in patients with hematological malignancies. Leuk Lymphoma 2020;61(14):3440–50. DOI:10.1080/10428194.2020.1808204.Niu A., Ning B., Socola F. et al. High mortality with high false negative rate: COVID-19 infection in patients with hematologic malignancies. Leuk Res 2021;106:106582. DOI:10.1016/j.leukres.2021.106582.Maia C., Martín-Sánchez E., Garcés J.J. et al. Immunologic characterization of COVID-19 patients with hematological cancer. Haematologica 2020;106(5):1457–60. DOI:10.3324/haematol.2020.269878.Lopez C.A., Chitty D., Chi J. et al. Outcomes in patients with hematological malignancies receiving anti-CD20 therapy in the setting of COVID-19 infection. Blood 2020;136:8–9. DOI:10.1182/blood-2020-143124.Wood W.A., Neuberg D.S., Thompson J.C. et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv 2020;4(23):5966–75. DOI:10.1182/bloodadvances.2020003170.Passamonti F., Cattaneo C., Arcaini L. et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020;7(10):e737–45. DOI:10.1016/S2352-3026(20)30251-9.Regalado-Artamendi I., JiménezUbieto A., Hernández-Rivas J.Á. et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. Hemasphere 2021;5(3):e538. DOI:10.1097/HS9.0000000000000538.Van Doesum J., Chinea A., Pagliaro M. et al. Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands. Leukemia 2020;34(9):2536–8. DOI:10.1038/s41375-020-0960-4.Lamure S., Dulery R., Delord M. et al. High incidence of persistent COVID-19 among patients with lymphoma treated with B-cell depleting immunotherapy. Clin Cancer Res 2021;27(6):S09–2. DOI:10.1158/1557-3265.COVID-1921-S09-02.Scarfò L., Chatzikonstantinou T., Rigolin G.M. et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 2020;34(9):2354–63. DOI:10.1038/s41375-020-0959-x.Treon S.P., Castillo J.J., Skarbnik A.P. et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020;135(21):1912–5. DOI:10.1182/blood.2020006288.Isidori A., de Leval L., Gergis U. et al. Management of patients with hematologic malignancies during the COVID-19 pandemic: practical considerations and lessons to be learned. Front Oncol 2020;10:1439. DOI:10.3389/fonc.2020.01439.Anti-CD20 Monoclonal Antibodies and Risk of Severe COVID-19 Infection and Death in Patients With Lymphoma. American Association for Cancer Research (AACR), Virtual Meeting Discussion, 2021. Available at: https://ascopost.com/issues/march-10-2021/anti-cd20monoclonal-antibodies-and-risk-ofsevere-covid-19-infection-and-death-inpatients-with-lymphoma/.ASH: COVID-19 and Indolent Lymphomas: Frequently Asked Questions. Available at: https://www.hematology.org/covid-19/covid-19-and-indolentlymphomas.FAI2R/SFR/SNFMI/SOFREMIP/CRI/ IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020;80(4):527–38. DOI:10.1136/annrheumdis-2020-218310.Avouac J., Drumez E., Hachulla E. et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 2021;3(6):e419–26. DOI:10.1016/S2665-9913(21)00059-X.Garcia-Fernandez A., Lopez-Gutierrez F., Loarce-Martos J. et al. Cohort of rheumatic patients treated with rituximab and COVID-19: does rituximab treatment increases the severity of SARS-COV2 infection? [abstract]. Arthritis Rheum 2020;72(suppl 10).Schulze-Koops H., Krueger K., Vallbracht I. et al. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 2021;80(5):e67. DOI:10.1136/annrheumdis-2020-218075.Esmaeili S., Abbasi M.H., Abolmaali M. et al. Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD. BMC Neurol 2021;21(1):183. DOI:10.1186/s12883-021-02218-4.Strangfeld A., Schäfer M., Gianfrancesco M.A. et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021;80(7):930–42. DOI:10.1136/annrheumdis-2020-219498.Quartuccio L., Treppo E., Binutti M. et al. Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis. Rheumatology (Oxford) 2021;60(7):3476–7. DOI:10.1093/rheumatology/keab175.Beketova T.V., Babak B.B., Suprun M.D. The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): the results of the first 8 months of the pandemic. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice 2021;59(1):37–46. (In Russ.). DOI:10.47360/1995-4484-2021-37-46.Бекетова Т.В., Бабак В.В., Супрун М.Д. Течение и исходы COVID-19 у пациентов с АНЦА-ассоциированными системными васкулитами, получающих лечение генно-инженерными биологическими препаратами (ритуксимаб, меполизумаб): итоги первых 8 месяцев пандемии. Научно-практическая ревматология 2021;59(1):37–46. DOI:10.47360/1995-4484-2021-37-46.Tepasse P.R., Hafezi W., Lutz M. et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 2020;190(2):185–8. DOI:10.1111/bjh.16896.Hoffmann M.S., Ganguly S. Delayed COVID-19 respiratory failure in patients with lymphoma on rituximab-based chemoimmunotherapy. Clin Lymphoma Myeloma Leuk 2021;21(6):e548–50. DOI:10.1016/j.clml.2021.02.009.Gelinck L.B., Teng Y.K., Rimmelzwaan G.F. et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007;66(10):1402–3. DOI:10.1136/ard.2007.071878.Yri O.E., Torfoss D., Hungnes O. et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011 Dec 22;118(26):6769–71. DOI:10.1182/blood-2011-08-372649.Van Assen S., Holvast A., Benne C.A. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62(1):75–81. DOI:10.1002/art.25033.Eisenberg R.A., Jawad A.F., Boyer J. et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 2013;33(2):388–96. DOI:10.1007/s10875-012-9813-x.Bedognetti D., Zoppoli G., Massucco C. et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximabcontaining regimens. J Immunol 2011;186(10):6044–55. DOI:10.4049/jimmunol.1004095.Salles G., Seymour J.F., Offner F. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377(9759):42–51. DOI:10.1016/S0140-6736(10)62175-7.Wang M., Salles G., Kumar A. et al. Role of maintenance rituximab after first-line bendamustine + rituximab or R-CHOP in patients with mantle cell lymphoma from a large US real-world cohort. Hematological Oncology. Supplement: 16th International Conference on Malignant Lymphoma, Virtual Edition 2021;39(S2):18–22. DOI:10.1002/hon.61_2880.Graf S.A., Stevenson P.A., Holmberg L.A. et al. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 2015;26(11):2323–8. DOI:10.1093/annonc/mdv364.Bose G., Galetta K. Reactivation of SARS-CoV-2 after rituximab in a patient with multiple sclerosis. Mult Scler Relat Disord 2021;52:102922. DOI:10.1016/j.msard.2021.102922.Lancman G., Mascarenhas J., Bar-Natan M. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol 2020;13(1):131. DOI:10.1186/s13045-020-00968-1.Devauchelle-Pensec V., Morvan J., Rat A.C. et al. Effects of rituximab therapy on quality of life in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 2011;29(1):6–12.Colucci M., Carsetti R., Cascioli S., et al. B Cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 2016;27(6):1811–22. DOI:10.1681/ASN.2015050523.Dunleavy K., Hakim F., Kim H.K. et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005;106(3):795–802. DOI:10.1182/blood-2004-08-3198.Bingham C.O.3rd, Looney R.J., Deodhar A. et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62(1):64–74. DOI:10.1002/art.25034.Hoyer B.F., Manz R.A., Radbruch A., Hiepe F. Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci 2005;1050:124–33. DOI:10.1196/annals.1313.014.Nakou M., Katsikas G., Sidiropoulos P. et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009;11(4):R131. DOI:10.1186/ar2798.Takata T., Suzumiya J., Ishikawa T. et al. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop 2009;49(1):9–13. DOI:10.3960/jslrt.49.9.Quinti I., Lougaris V., Cinzia Milito C. et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J All Clin Immunol 2020;146(1):211–3.e4. DOI:10.1016/j.jaci.2020.04.013.Soresina A., Moratto D., Chiarini M. et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol 2020;31(5):565–9. DOI:10.1111/pai.13263.Bercovici N., Duffour M.T., Agrawal S. et al. New methods for assessing T-cell responses. Clin Diagn Lab Immunol 2000;7(6):859–64. DOI:10.1128/CDLI.7.6.859-864.2000.Ten Brinke A., Marek-Trzonkowska N., Mansilla M.J. et al. Monitoring T-cell responses in translational studies: optimization of dye-based proliferation assay for evaluation of antigen-specific responses. Front Immunol 2017;8:1870. DOI:10.3389/fimmu.2017.01870.Re D., Barrière J., Chamorey E. et al. Low rate of seroconversion after mRNA antiSARS-CoV-2 vaccination in patients with hematological malignancies. Leuk Lymphoma 2021;62(13):3308–10. DOI:10.1080/10428194.2021.1957877.Herishanu Y., Avivi I., Aharon A. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021;137(23):3165–73. DOI:10.1182/blood.2021011568.Chilimuri S., Mantri N., Zahid M., Sun H. COVID-19 vaccine failure in a patient on rituximab therapy. Rheumatol Adv Pract 2021;5(2):rkab038. DOI:10.1093/rap/rkab038.Teh B.W., Tam C.S. Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy. Leuk Lymphoma 2021;62(12):2820–2. DOI:10.1080/10428194.2021.1957879.Ellwardt E., Ellwardt L., Bittner S., Zipp F. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol Neuroimmunol Neuroinflamm 2018;5(4):e463. DOI:10.1212/NXI.0000000000000463.Thiel J., Rizzi M., Engesser M. et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther 2017;19(1):101. DOI:10.1186/s13075-017-1306-0.Kant S., Kronbichler A., Salas A. et al. Timing of COVID-19 vaccine in the setting of anti-CD20 therapy: a primer for nephrologists. Kidney Int Rep 2021;6(5):1197–9. DOI:10.1016/j.ekir.2021.03.876.Furer V., Rondaan C., Heijstek M.W. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79(1):39–52. DOI:10.1136/annrheumdis-2019-215882.Bonelli M.M., Mrak D., Perkmann T. et al. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis 2021;80(10):1355–6. DOI:10.1136/annrheumdis-2021-220408.Kamar N., Abravanel F., Marion O. et al. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. N Engl J Med 2021;385(7):661–2. DOI:10.1056/NEJMc2108861.Hill J.A., Ujjani C.S., Greninger A.L. et al. Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient. Cancer Cell 2021;39(8):1037–8. DOI:10.1016/j.ccell.2021.06.015.Graalmann T., Borst K., Manchanda H. et al. B cell depletion impairs vaccinationinduced CD8+ T cell responses in a type I interferon-dependent manner. Ann Rheum Dis 2021;80(12):1537–44. DOI:10.1136/annrheumdis-2021-220435.Monin L., Laing A.G., Muñoz-Ruiz M. et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765–78. DOI:10.1016/S1470-2045(21)00213-8.Mehta P., Porter J.C., Chambers R.C. et al. B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? Lancet Rheumatol 2020;2(10):e589–90. DOI:10.1016/S2665-9913(20)30270-8.Zhao J., Yuan Q., Wang H. et al. Antibodyresponses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020;71(16):2027–34. DOI:10.1093/cid/ciaa344.Woodruff M.C., Ramonell R.P., Cashman K.S. et al. Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation. medRxiv 2020. DOI:10.1101/2020.04.29.20083717.Iwasaki A., Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol 2020;20:339–41. DOI:10.1038/s41577-020-0321-6.Mehta P., McAuley D.F., Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–4. DOI:10.1016/S0140-6736(20)30628-0.Fill L., Hadney L., Graven K. et al. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019. Ann Allergy Asthma Immunol 2020;125(1):112–4. DOI:10.1016/j.anai.2020.04.033.Wen X.S., Jiang D., Gao L. et al. Clinical characteristics and predictive value of lower CD4+T cell level in patients with moderate and severe COVID-19: a multicenter retrospective study. BMC Infect Dis 2021;21(1):57. DOI:10.1186/s12879-020-05741-w.Liu Z., Long W., Tu M. et al. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect 2020;81(2):318–56. DOI:10.1016/j.jinf.2020.03.054.García Muñoz R., Izquierdo-Gil A., Muñoz A. et al. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent nonHodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol 2014;93(11):1879–87. DOI:10.1007/s00277-014-2135-8.Melet J., Mulleman D., Goupille P. et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum 2013;65(11):2783–90. DOI:10.1002/art.38107.Kravchenko S., Sychevskaya K., Babaeva F., Misurina A. High risk of COVID-19 associated mortality in follicular lymphoma patients on antiCD20 maintenance. The 83rd Annual Meeting of the Japanese Society of Hematology. Book of Abstracts. Best Poster Award Session. 2021. P. 661.